46-83% of CPAP users fail to meet the minimum 4-hour adherence threshold, and the Philips Respironics recall left 15 million patients without safe devices

Between 46% and 83% of patients prescribed CPAP therapy for obstructive sleep apnea fail to use their device the minimum 4 hours per night needed for clinical benefit, and this chronic non-adherence crisis was compounded in June 2021 when Philips Respironics issued a Class I recall of 15 million CPAP, BiPAP, and ventilator devices worldwide due to degrading polyester-based polyurethane sound abatement foam that patients had been inhaling. Why it matters: non-adherent patients revert to untreated sleep apnea with all its cardiovascular, metabolic, and cognitive consequences, so the billions spent on device prescription, titration studies, and follow-up visits produce no clinical return, so insurers respond by imposing strict 90-day compliance monitoring and clawing back coverage for non-compliant patients, so patients who struggle with mask fit or claustrophobia lose access to the only first-line therapy rather than receiving alternatives, so the recall then removed devices from millions of the patients who were compliant, forcing them to choose between using a potentially carcinogenic device or going untreated during a multi-year replacement backlog. The structural root cause is that CPAP requires a patient to tolerate forced air through a mask every night for the rest of their life, yet the device fitting process typically involves a single in-lab or remote session with minimal long-term behavioral support, and the insurance reimbursement model treats CPAP as a binary pass/fail compliance metric rather than funding the iterative mask fitting, pressure adjustment, and behavioral coaching that adherence research shows is necessary.